Page 122 - 202008

al. TIPS versus drug therapy in preventing varicealrebleed- effect of beta-blockers in patients with cirrhosis，portal hy-
ing in advanced cirrhosis：a randomized controlled trial[J]. pertension and ascites[J]. Am J Med Sci，2016，351（2）：
Hepatology，2002，35（2）：385-392. 169-176.
[ 8 ] SHAH HA，AZAM Z，RAUF J，et al. Carvedilol vs. esoph- [19] BOSSEN L，KRAG A，VILSTRUP H，et al. Non-selective
ageal variceal band ligation in the primary prophylaxis of β-blockers do not affect mortality in cirrhosis patients
variceal hemorrhage：a multicentre randomized controlled with ascites：post hoc analysis of three RCTs with 1 198
trial[J]. J Hepatol，2014，60（4）：757-764. patients[J]. Hepatology，2016，63（6）：1968-1976.
[ 9 ] LO GH，CHEN WC，CHEN MH，et al. Endoscopic liga- [20] ONALI S，KALAFATELI M，MAJUMDAR A，et al. Non-
tion vs. nadolol in the prevention of first variceal bleeding selective beta-blockers are not associated with increased
in patients with cirrhosis[J]. Gastrointest Endosc，2004，59 mortality in cirrhotic patients with ascites[J]. Liver Int，
（3）：333-338. 2017，37（9）：1334-1344.
[10] BORRONI G，SALERNO F，CAZZANIGA M，et al. Nad- [21] BHUTTA AQ，GARCIA-TSAO G，REDDY KR，et al. Be-
olol is superior to isosorbidemononitrate for the preven- ta-blockers in hospitalized patients with cirrhosis and asci-
tion of the first variceal bleeding in cirrhotic patients with tes：mortality and factors determining discontinuation and
ascites[J]. J Hepatol，2002，37（3）：315-321. reinitiation[J]. Aliment Pharmacol Ther，2018，47（1）：
[11] CHOLONGITAS E，PAPATHEODORIDIS GV，MANE- 78-85.
SIS EK，et al. Spontaneous bacterial peritonitis in cirrhot- [22] BOSCH J，GARCIA-PAGAN JC. Prevention of varicealre-
ic patients：is prophylactic propranolol therapy benefi- bleeding[J]. The Lancet，2003，361（9361）：952-954.
cial? [J]. J Gastroenterol Hepatol，2006，21（3）：581-587. [23] KIM SG，LARSON JJ，LEE JS，et al. Beneficial and harm-
[12] ROBINS AE，BOWDEN A，WATSON W，et al. DTU-001 ful effects of nonselective beta blockers on acute kidney
propanolol at modest dose does not impair survival in pa- injury in liver transplant candidates[J]. Liver Transplantat，
tients with cirrhosis and refractory ascites[J]. Gut，2012. 2017，23（6）：733-740.
DOI：10.1136/gutjnl-2012-302514c.1. [24] FERRARESE A，TIKHONOFF V，CASIGLIA E，et al.
[13] LEITHEAD JA，RAJORIYA N，TEHAMI N，et al. Non- Hemodynamic evaluation of nonselective β-blockers in pa-
selective β-blockers are associated with improved survival tients with cirrhosis and refractory ascites[J]. Gastroenter-
in patients with ascites listed for liver transplantation[J]. ol Res Pract，2018. DOI：10.1155/2018/4098210.
Gut，2015. DOI：1136/gutjnl-2013-306502. [25] KRAG A，WIEST R，ALBILLOS A，et al. The window hy-
[14] BANG UC，BENFIELD T，HYLDSTRUP L，et al. Effect pothesis：haemodynamic and non-haemodynamic effects
of propranolol on survival in patients with decompensated of beta-blockers improve survival of patients with cirrho-
cirrhosis：a nationwide study based Danish patient regis- sis during a window in the disease[J]. Gut，2012. DOI：
ters[J]. Liver Int，2016，36（9）：1304-1312. 10.1136/gutjnl-2011-301348.
[15] MAZHAR K，ELLIOTT AC，ROCKEY DC. The benefi- [26] SAKKARIN C，VALENTIN N，ALAHDAB F，et al. Non-
cial effect of beta-blockers in patients with cirrhosis，por- selective β-blockers and survival in patients with cirrhosis
tal hypertension，and ascites[J]. Gastroenterology，2013. and ascites：a systematic review and meta-analysis[J].
DOI：10.1016/S0016-5085（13）63514-3. Clin Gastroenterol Hepatol，2016，14（8）：1096-1104.
[16] MANDORFER M，BOTA S，SCHWABL P，et al. Nonse- [27] NJEI B，MCCARTY TR，GARCIA-TSAO G. Beta-block-
lective β-blockers increase risk for hepatorenal syndrome ers in patients with cirrhosis and ascites：type of be-
and death in patients with cirrhosis and spontaneous bacte- ta-blocker matters[J]. Gut，2016，65（8）：1393-1394.
rial peritonitis[J]. Gastroenterology，2014. DOI：10.1053/j. [28] BOSCH J. Carvedilol for portal hypertension in patients
gastro.2014.03.005. with cirrhosis[J]. Hepatology，2010，51（6）：2214-2218.
[17] KIMER N，FEINEIS M，MØLLER S，et al. Beta-blockers [29] THORHAUGE KH，LINDVIG KP，LALEMAN W，et al.
in cirrhosis and refractory ascites：a retrospective cohort Lack of consensus forusage of β-blockers in end-stage liver
study and review of the literature[J]. Scand J Gastroenter- disease[J]. Gut，2016. DOI：10.1136/gutjnl-2016-311573.
ol，2015，50（2）：129-137. （收稿日期：2019-11-21 修回日期：2020-03-05）
[18] ADAY AW，MAYO MJ，ELLIOTT A，et al. The beneficial （编辑：孙 冰）

·1008 · China Pharmacy 2020 Vol. 31 No. 8 中国药房 2020年第31卷第8期